← back to search

Ted Wun

Southern California Clinical and Translational Science Institute · US
Area of research
Genetics · Internal Medicine
Research interest
Research interests include Hemoglobinopathies and Related Disorders, Venous Thromboembolism Diagnosis and Management, Iron Metabolism and Disorders, and Acute Lymphoblastic Leukemia research.
h-index
43
citations
6,474
works
152
NIH funding
primary concept
Medicine
email

Recent publications

Peripheral Neuropathy Incidence in Children, and Adolescents and Young Adults With Cancer and Medicaid Insurance in California.
2026cited by 1position: contributordoi
Safety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries.
2026cited by 0position: contributordoi
Low bone mineral density and pain impact in adults with sickle cell disease.
2026cited by 0position: contributordoi
Quality of Cancer Care in California After Full Implementation of the Affordable Care Act: Findings From a Population-Based Study
American Journal of Preventive Medicine 2026cited by 0position: contributordoi
ASH sickle cell disease CPKD guidelines report.
2025cited by 0position: contributordoi
The clinical spectrum of <scp>HbSC</scp> sickle cell disease‐not a benign condition
British Journal of Haematology 2024cited by 19position: middledoi
The clinical spectrum of HbSC sickle cell disease-not a benign condition.
2024cited by 12position: contributordoi
Late endocrine diseases in survivors of adolescent and young adult cancer in California: a population-based study.
2024cited by 5position: contributordoi
Rates of strokes in Californians with sickle cell disease in the post-STOP era.
2024cited by 5position: contributordoi
Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018.
2024cited by 4position: contributordoi
Association of IVCF use with mortality and intracranial hemorrhage in patients with selected cancers and brain metastasis.
2024cited by 0position: contributordoi
Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry.
2024cited by 0position: contributordoi
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Journal of Clinical Oncology 2023cited by 47position: middledoi
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
2023cited by 35position: contributordoi
Pregnancy outcomes in women with sickle cell disease in California
American Journal of Hematology 2023cited by 34position: lastdoi
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis.
2023cited by 32position: contributordoi
Sickle Cell Disease
JAMA 2022cited by 410position: lastdoi
The incidence of cancer-associated thrombosis is increasing over time.
2022cited by 95position: contributordoi
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis
Blood 2022cited by 41position: middledoi
Racial disparities in cancer-associated thrombosis.
2022cited by 22position: contributordoi
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI.
2022cited by 13position: contributordoi
Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment.
2022cited by 10position: contributordoi
COVID-19 and venous thromboembolism risk in patients with sickle cell disease.
2022cited by 7position: contributordoi
Linking the Center for International Blood and Marrow Transplant Research Registry to the California Cancer Registry and California Hospital Patient Discharge Data.
2022cited by 6position: contributordoi
Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors.
2022cited by 4position: contributordoi
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.
2021cited by 16position: contributordoi
Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population‐based study
Pediatric Blood & Cancer 2021cited by 8position: middledoi
Building an institutional K awardee program at UC Davis through utilization of CTSA resources.
2021cited by 2position: contributordoi
Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium
American Journal of Hematology 2020cited by 51position: middledoi
Bleeding in patients with sickle cell disease: a population-based study.
2020cited by 30position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 27 papers (2019–2026)Theresa H.M. Keegan · UC Davis Comprehensive Cancer Center10 papers (2018–2026)Ann Brunson · California State University, Sacramento9 papers (2020–2026)Renata Abrahão · Center For Policy Research7 papers (2022–2026) · 6 papers (2022–2026)Julie Kanter · University of Alabama at Birmingham5 papers (2018–2024)Marsha Treadwell · Cincinnati Children's Hospital Medical Center5 papers (2018–2020)Victor R. Gordeuk · University of Illinois Chicago4 papers (2018–2024)Nirmish Shah · University of Pittsburgh Medical Center4 papers (2018–2024)Lori Muffly · Stanford Health Care3 papers (2022–2024)Lewis L. Hsu · University of Illinois Chicago3 papers (2015–2024) · 3 papers (2018–2024) · 3 papers (2015–2022)Jeffrey Glassberg · Icahn School of Medicine at Mount Sinai3 papers (2018–2024)Helen Thackray · BioCryst Pharmaceuticals (United States)3 papers (2015–2022)Jeffery J. Auletta · Creative Health Care Management3 papers (2022–2024)John L. Magnani · University of Georgia3 papers (2015–2022)Julie Kanter · National Blood Clot Alliance3 papers (2023–2024)Lindsay M. Morton · Arizona State University3 papers (2022–2024) · 3 papers (2022–2024)